SC 13G/A: CASI Pharmaceuticals, Inc.

AI Summary

SC 13G/A filing by CASI Pharmaceuticals, Inc..

Risk Assessment

Risk Level: low

FAQ

Key Financial Figures

• $0.0001 — ecurities: Ordinary Shares, par value $0.0001 per share (Ordinary Shares) (e) CUSI

Filing Documents

• d846894dsc13ga.htm (SC 13G/A) — 84KB
• 0001193125-24-246519.txt ( ) — 86KB

From the Filing

SC 13G/A 1 d846894dsc13ga.htm SC 13G/A SC 13G/A Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5)* CASI Pharmaceuticals, Inc. (Name of Issuer) Ordinary Shares (Title of Class of Securities) G1933S101 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting persons initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. G1933S101 Schedule 13G Page 1 of 8 1 Names of Reporting Persons Panacea Venture Healthcare Fund II, L.P. 2 Check the Appropriate Box if a Member of a Group (a)(b) 3 SEC Use Only 4 Citizenship or Place of Organization Cayman Islands Number of Shares Beneficially Owned by Each Reporting Person With 5 Sole Voting Power 0 6 Shared Voting Power 1,323,429 7 Sole Dispositive Power 0 8 Shared Dispositive Power 1,323,429 9 Aggregate Amount Beneficially Owned by Each Reporting Person 1,323,429 10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares Not Applicable 11 Percent of Class Represented by Amount in Row 9 8.6% 12 Type of Reporting Person PN CUSIP No. G1933S101 Schedule 13G Page 2 of 8 1 Names of Reporting Persons Panacea Venture Healthcare Fund II GP Company, Ltd. 2 Check the Appropriate Box if a Member of a Group (a)(b) 3 SEC Use Only 4 Citizenship or Place of Organization Cayman Islands Number of Shares Beneficially Owned by Each Reporting Person With 5 Sole Voting Power 0 6 Shared Voting Power 1,323,429 7 Sole Dispositive Power 0 8 Shared Dispositive Power 1,323,429 9 Aggregate Amount Beneficially Owned by Each Reporting Person 1,323,429 10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares Not Applicable 11 Percent of Class Represented by Amount in Row 9 8.6% 12 Type of Reporting Person CO CUSIP No. G1933S101 Schedule 13G Page 3 of 8 1 Names of Reporting Persons Panacea Innovation Limited 2 Check the Appropriate Box if a Member of a Group (a)(b) 3 SEC Use Only 4 Citizenship or Place of Organization Cayman Islands Number of Shares Beneficially Owned by Each Reporting Person With 5 Sole Voting Power 0 6 Shared Voting Power 1,323,429 7 Sole Dispositive Power 0 8 Shared Dispositive Power 1,323,429 9 Aggregate Amount Beneficially Owned by Each Reporting Person 1,323,429 10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares Not Applicable 11 Percent of Class Represented by Amount in Row 9 8.6% 12 Type of Reporting Person CO CUSIP No. G1933S101 Schedule 13G Page 4 of 8 1 Names of Reporting Persons James Huang 2 Check the Appropriate Box if a Member of a Group (a)(b) 3 SEC Use Only 4 Citizenship or Place of Organization Republic of China Number of Shares Beneficially Owned by Each Reporting Person With 5 Sole Voting Power 111,571 6 Shared Voting Power 1,323,429 7 Sole Dispositive Power 111,571 8 Shared Dispositive Power 1,323,429 9 Aggregate Amount Beneficially Owned by Each Reporting Person 1,435,000 10 Check if the Aggregate Amount in Row (9) Excludes Certain Shares Not Applicable 11 Percent of Class Represented by Amount in Row 9 9.2% 12 Type of Reporting Person IN CUSIP No. G1933S101 Schedule 13G Page 5 of 8 ITEM1. (a) Name of Issuer: CASI Pharmaceuticals, Inc. (the Issuer). (b) Address of Issuers Principal Executive Offices: 1701-1702, China Central Office Tower 1 No. 81 Jianguo Road, Chaoyang District, Beijing Peoples Republic of China. ITEM2. (a) Name of Person Filing: Each of the following is hereinafter individually referred to as a Reporting Person and collectively as the Reporting Persons. This statement is filed on behalf of: Panacea Venture Healthcare Fund II, L.P. Panacea Venture Healthcare Fund II GP Company, Ltd. Panacea Innovation Limited James Huang (b) Address of Principal Business Office: The business address of each of the Reporting Persons is c/o Maples Corporate Services Limited, Ugland House, G

View Full Filing

View this SC 13G/A filing on SEC EDGAR